Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

LEO Pharma ItaliaLEO Pharma Italia
VS
AUROBINDO PHARMA LTDAUROBINDO PHARMA LTD
LEO Pharma Italia

LEO Pharma Italia

Via Elio Vittorini, 129, Roma, 00144, IT

Last Update: 09/06/2026

View Profile
Between 750 and 799
http://www.leo-pharma.it
757/1000Fair

LEO Pharma è un’azienda farmaceutica danese, fondata nel 1908, leader a livello mondiale nella cura delle patologie dermatologiche. LEO Pharma vanta una presenza in più di 60 Paesi e commercializza i suoi prodotti in oltre 130 mercati. L’azienda ha dedicato decenni all...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:None
Subsidiaries:5
12-month incidents
0
Known data breaches
0
Attack type number
0
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, 500032, IN

Last Update: 03/04/2026

View Profile
Between 750 and 799
https://www.aurobindo.com/
778/1000Fair

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, brand...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:14,862
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
LEO Pharma Italia

LEO Pharma Italia

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for LEO Pharma Italia in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2026.

Incidents

Incident History - LEO Pharma Italia (X = Date, Y = Severity)

LEO Pharma Italia cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
LEO Pharma Italia

LEO Pharma Italia

Incidents
No explicit notable incidents reported.
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

Incidents
No explicit notable incidents reported.

FAQ

Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has the best AI Cybersecurity Score ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has experienced more cyber incidents in the past ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has experienced more cyber incidents this year ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has experienced at least one ransomware attack ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has experienced at least one data breach ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has experienced at least one targeted cyberattack ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has experienced at least one vulnerability ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one holds the most compliance certifications ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one holds the fewest compliance certifications ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has the most subsidiaries ?
Between LEO Pharma Italia company and AUROBINDO PHARMA LTD company, which one has the largest number of employees ?
Between LEO Pharma Italia and AUROBINDO PHARMA LTD, which company holds both SOC 2 Type 1 certifications ?
Between LEO Pharma Italia and AUROBINDO PHARMA LTD, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - LEO Pharma Italia or AUROBINDO PHARMA LTD ?
Which company is PCI DSS compliant - LEO Pharma Italia or AUROBINDO PHARMA LTD ?
Between LEO Pharma Italia and AUROBINDO PHARMA LTD, which company complies with HIPAA regulations for healthcare data ?
Between LEO Pharma Italia and AUROBINDO PHARMA LTD, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-9693
SUMMARY

Mattermost versions 10.11.x <= 10.11.20, 11.7.x <= 11.7.5 Mattermost fails to remove thread membership records when a user is removed from or leaves a team, which allows a previously removed user who is later re-invited to the team to view private channel thread root post content and metadata via the team threads API.. Mattermost Advisory ID: MMSA-2026-00682

PUBLISHED
Date2026-08-17
UPDATED
Date2026-08-17
RISK INFORMATION (Score: 3.5)
CVSS3
Base Score: 3.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.1
REFERENCES
CVE-2026-75587
SUMMARY

Mattermost Desktop App versions <=6.2 6.2.2.0 fail to redact the pre-auth secret when generating a diagnostics report, which allows a local attacker with access to a user's diagnostics report or log files to obtain the plaintext pre-auth secret configured for a connected server via inspecting the Server Connectivity (Step-3) diagnostics output. Mattermost Advisory ID: MMSA-2026-00716

PUBLISHED
Date2026-08-17
UPDATED
Date2026-08-17
RISK INFORMATION (Score: 3.6)
CVSS3
Base Score: 3.6
Complexity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:C/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
1.8
REFERENCES
CVE-2026-75078
SUMMARY

A security flaw has been discovered in SourceCodester Class and Exam Timetabling System 1.0. This affects an unknown part of the file /BSHRM1.php. Performing a manipulation of the argument course results in cross site scripting. Remote exploitation of the attack is possible. The exploit has been released to the public and may be used for attacks.

PUBLISHED
Date2026-08-17
UPDATED
Date2026-08-17
RISK INFORMATION (Score: 4.3)
CVSS2
Base Score: 5.0
Complexity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
REFERENCES
CVE-2026-67961
SUMMARY

An issue in O2OA v.10.0.2 allows a local attacker to execute arbitrary code via the the sandbox mechanism of the Invoke script execution.

PUBLISHED
Date2026-08-17
UPDATED
Date2026-08-17
IMPACT SCORE
NA
EXPLOITABILITY
NA
REFERENCES
CVE-2026-67919
SUMMARY

An issue in Halo 2.25.4 allows a remote attacker to execute arbitrary code via the PluginEndpoint.java, installFromUri method, and DefaultPluginApplicationContextFactory components

PUBLISHED
Date2026-08-17
UPDATED
Date2026-08-17
IMPACT SCORE
NA
EXPLOITABILITY
NA
REFERENCES